I. NGD 94-1: Identification of a novel, high-affinity antagonist at the human dopamine D4 receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 2, 1997, Pages 1011-1019

  Tallman, John F ^a   Primus, Renee J ^a   Brodbeck, Robbin ^a   Cornfield, Linda ^a,b   Meade, Robin ^a   Woodruff, Kristine ^a,c   Ross, Phillip ^a,d   Thurkauf, Andrew ^a   Gallager, Dorothy W ^a  

^a NEUROGEN CORPORATION   (United States)

^b BAYER CORPORATION   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYL 4 [4 (2 PYRIMIDINYL) 1 PIPERAZINYLMETHYL]IMIDAZOLE; 2 PHENYL 4 [4 (2 PYRIMIDYL)PIPERAZINYL]METHYLIMIDAZOLE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR AFFECTING AGENT; GUANOSINE TRIPHOSPHATE; QUINPIROLE; RECEPTOR SUBTYPE; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; CHO CELL; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEPTOR AFFINITY; RECEPTOR DENSITY;

ANIMALS; CHO CELLS; CRICETINAE; DOPAMINE ANTAGONISTS; GTP-BINDING PROTEINS; GUANOSINE TRIPHOSPHATE; HUMANS; IMIDAZOLES; PYRIMIDINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; TRITIUM;

EID: 0030743501     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. 4 receptor variants. J. Neurochem. 65: 1157-1165, 1995.
2. 3H]SCH 23390, a selective D-1 receptor antagonist ligand, rat striatum. Life Sci. 35: 1885-1893, 1984.
3. BYLUND, D. B. AND YAMAMURA, H. I.: Methods for receptor binding. In Methods in Neurotransmitter Receptor Analysis, ed. by H. I. Yamamura, S. J. Enna and M. J. Kuhar, pp. 25-32, Raven Press, New York, 1990.
4. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
5. CIVELLI, O.: Molecular biology of the dopamine receptor subtypes. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp.155-161, Raven Press, New York, 1995.
6. 2 receptor: Two molecular forms generated by alternative splicing. EMBO J. 8: 4025-4034, 1989.
7. DUMONT, Y., FOURNEIR, A. ST-PIERRE AND QUIRION, R.: Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J. Neurosci. 13: 73-86, 1993.
8. 2 dopamine receptor isoforms. Nature 342: 923-926, 1989.
9. GORDON, E. A., KOHOUT, T. A. AND FISHMAN, P. H.: Characterization of functional neuropeptide Y receptors in a human neuroblastoma cell line. J. Neurochem. 55: 506-513, 1990.
10. 3H-OHDPAT. Nature 305: 140-142, 1983.
11. GRAHAM, F. L. AND VAN DER E. B., A. J.: A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456-467, 1973.
12. 2 dopamine receptor. Proc. Natl. Acad. Sci. U.S.A. 86: 9762-9766, 1989.
13. 3H-prazosin to rat brain a-adrenergic receptors. Eur. J. Pharmacol. 55: 323-326, 1979.
14. 2 dopamine receptors from the high-to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotides. J. Neurochem. 44: 1925-1935, 1985.
15. HILL, P., LAI, Y., HNILO, J., LIN, C., KARLA, M., BOUNDS, S., HERZ, J. AND MITCHELL, R.: Cloning, expression, and comparison of the binding characteristics of the known human dopamine receptors. Adv. Neurol. 69: 41-52, 1996.
16. HOWLETT, D. R., TAYLOR, P. AND WALTER, D. S.: a-Adrenergic selectivity studies RX 781094 using radioligand binding to cerebral membranes. Br. J. Pharmacol. 76: 294P, 1982.
17. LAHTI, R. A., ROBERT, R. C., CONLEY, R. R., COCHRANE, E. V., MUTIN, A. AND TAMMINGA, C. A.: D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. Neuroreport 7: 1945-1948, 1996.
18. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol. 236: 483-486, 1993.
19. LAHTI, R. A., FIGUR, L. M., PIERCEY, P. L., RUPPEL, P. L. AND EVANS, D. L.: Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: Utilization of receptor state binding affinities. Mol. Pharmacol. 42: 432-438, 1992.
20. 2 receptor sites. Mol. Pharmacol. 21: 301-314, 1982.
21. 4 (DRD4) gene. Hum Mol. Genet. 2: 767-773, 1993.
22. LOBAUGH, L. A. AND BLACKSHEAR, P. J.: Neuropeptide Y binding and inhibition of cAMP accumulation in human neuroepithelioma cells. Am. J. Physiol. 258: C913-C922, 1990.
23. LOO, P. A., BRAUNWALDER, A. F., LEHMANN, J. AND WILLIAMS, M.: Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists. Eur. J. Pharmacol. 123: 467-468, 1986.
24. MEADOR-WOODRUFF, J. H., GRANDY, D. K., VAN TOL, H. H. M., DAMASK, S. P., LITTLE, K. Y., CIVELLI, O. AND WATSON, S. J.: Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 10: 239-248, 1994.
25. MONSMA, F. J., MCVITTIE, L. D., GERFEN, C. R., MAHAN, L. C. AND SIBLEY, D. R.: Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 342: 926-929, 1989.
26. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15: 2186-2191, 1995.
27. 4 receptor polymorphism and schizophrenia. Proc. Jpn. Acad. 71: 241-243, 1995.
28. 3H]YM 09151-2. Naunyn-Schmiedeberg's Arch. Pharmacol. 329: 333-343, 1985.
29. 2-like selective agonists and partial agonists. Soc. Neurosci. Abstr. 21: 620, 1995.
30. PAZOS, A., HOYER, D. AND PALACIOS, J. M.: The binding of serotonergic ligands to the porcine choroid plexus. Eur. J. Pharmacol. 106: 539-546, 1985.
31. 4 receptor gene and schizophrenia. Am. J. Med. Genet. 60: 452-455, 1995.
32. 4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch. Gen. Psychiatry 51: 912-917, 1994.
33. 4 receptors in the action and development of antipsychotic agents. Drugs 51: 7-11, 1996.
34. 4 receptors in drug-treated schizophrenia. Eur. J. Pharmacol. 281: R5-R6, 1995.
35. SEEMAN, P.: Therapeutic receptor-blocking concentrations of neuroleptics. Int. Clin. Psychopharmacol. 10: 5-13, 1995.
36. 4 receptor varies with the affinity of the competing radioligand. Eur. J. Pharmacol. 291: 59-66, 1995.
37. SEEMAN, P. AND VAN TOL, H. H. M.: Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15: 264-270, 1994.
38. 4 receptors elevated in schizophrenia. Nature 365: 441-445, 1993.
39. SIBLEY, D. R. AND MONSMA, F. J.: Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13: 61-68, 1992.
40. 4 receptor in postmortem caudate nucleus of subjects with schizophrenia. Soc. Neurosci. Abstr. 20: 912, 1994.
41. SUNAHARA, R. K., NIZNIK, H. B., WEINER, D. M., STORMANN, T. M., BRANN, M. R., KENNEDY, J. L., GELEINTER, J. E., ROZMAHEL, R., YANG, Y., ISREAL, Y., SEEMAN, P. AND O'DOWD, B. F.: Human dopamine-D1 receptor encoded by an intronless gene on chromosome-5. Nature 347: 80-83, 1990.
42. 1. Nature 350: 614-619, 1991.
43. 1D receptor subtypes. J. Recep. Signal Transduct. 15: 199-211, 1995.
44. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614, 1991.
45. 4 receptor variants in the human population. Nature 358: 149-152, 1992.
46. 3H]tolyl)guanidine: A selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. U.S.A. 83: 8784-8788, 1986.
47. WIELAND, T. AND JAKOBS, K. H.: Measurement of receptor-stimulated guanosine 5′-Ο-(γ-Thio)triphosphate binding by G proteins. Methods Enzymol. 237: 3-13, 1994.
48. ZAHNISER, N. R. AND MOLINOFF, P. B.: Effect of guanine nucleotides on striatal dopamine receptors. Nature. 275: 453-455, 1978.